Skip to content

Recent Press Releases

Apr 22, 2014

Allergan Adopts One-Year Stockholder Rights Plan  

Apr 22, 2014

Allergan Confirms Receipt of Unsolicited Proposal from Valeant  

Apr 21, 2014

Allergan Notes Public Filings by Valeant and Pershing Square  

Apr 4, 2014

Allergan Announces Quarterly Conference Call  

Mar 13, 2014

Survey Shows 3 Out Of 4 Women In The U.S. (Ages 18-65) Think The Length, Thickness, Or Color Of Their Eyelashes Is Inadequate1  

Feb 5, 2014

Allergan Reports Fourth Quarter 2013 Operating Results  

Jan 9, 2014

Allergan Announces Quarterly Conference Call  

Jan 7, 2014

Allergan, Inc. and Medytox, Inc. Complete Licensing Agreement  

Dec 2, 2013

Allergan, Inc. Completes Sale of Obesity Intervention Business  

Nov 5, 2013

November is Bladder Health Awareness Month - What's Your Bladder IQ?  

Oct 29, 2013

Allergan Reports Third Quarter 2013 Operating Results  

Oct 23, 2013

FDA Approves JUVÉDERM VOLUMA™ XC  

Oct 23, 2013

Allergan's VISTABEL® (botulinum toxin type A) Receives Europe's First Positive Opinion for Treatment of Moderate to Severe Lateral Canthal Lines (Crow's Feet Lines) in Adult Patients  

Oct 7, 2013

Study Published in PLOS ONE Demonstrates Cost Recovery for Laparoscopic Adjustable Gastric Band in Less than Two Years and Significant Cost Savings Over Time for Morbidly Obese Patients  

Oct 4, 2013

Allergan Announces Quarterly Conference Call  

Sep 25, 2013

Allergan, Inc. and Medytox, Inc. to Enter into Licensing Agreement  

Sep 11, 2013

FDA Approves BOTOX® Cosmetic (onabotulinumtoxinA) for Temporary Improvement of Moderate to Severe Lateral Canthal Lines (Crow's Feet Lines) in Adults  

Sep 10, 2013

Allergan's BOTOX® (botulinum toxin type A) Receives Authorisation for the Treatment of Overactive Bladder in the UK  

Jul 31, 2013

Allergan Reports Second Quarter 2013 Operating Results  

Jun 28, 2013

Allergan Announces Quarterly Conference Call  

Showing 1-20 of 358
Page: 1 2 3 ... 18
 Next 20